JP2010534243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534243A5 JP2010534243A5 JP2010518230A JP2010518230A JP2010534243A5 JP 2010534243 A5 JP2010534243 A5 JP 2010534243A5 JP 2010518230 A JP2010518230 A JP 2010518230A JP 2010518230 A JP2010518230 A JP 2010518230A JP 2010534243 A5 JP2010534243 A5 JP 2010534243A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- agent
- antibody
- item
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 20
- 206010052779 Transplant rejections Diseases 0.000 claims description 14
- 239000003018 immunosuppressive agent Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 11
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 11
- 230000001861 immunosuppressant effect Effects 0.000 claims description 11
- 239000002955 immunomodulating agent Substances 0.000 claims description 10
- 229940121354 immunomodulator Drugs 0.000 claims description 10
- 230000002584 immunomodulator Effects 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 10
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims description 8
- 229930105110 Cyclosporin A Natural products 0.000 claims description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 8
- 108010036949 Cyclosporine Proteins 0.000 claims description 8
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims description 8
- 229960001265 ciclosporin Drugs 0.000 claims description 8
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 8
- 229960002930 sirolimus Drugs 0.000 claims description 8
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 230000004083 survival effect Effects 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims description 4
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims description 4
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 102000006395 Globulins Human genes 0.000 claims description 4
- 108010044091 Globulins Proteins 0.000 claims description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000007774 longterm Effects 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 238000011316 allogeneic transplantation Methods 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 238000002689 xenotransplantation Methods 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 230000006978 adaptation Effects 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 230000001494 anti-thymocyte effect Effects 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- 229960004669 basiliximab Drugs 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960002806 daclizumab Drugs 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 230000008348 humoral response Effects 0.000 claims description 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 2
- 210000004153 islets of langerhan Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960003816 muromonab-cd3 Drugs 0.000 claims description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000008629 immune suppression Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000012177 negative regulation of immune response Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 44
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96202207P | 2007-07-25 | 2007-07-25 | |
| PCT/US2008/009037 WO2009014745A1 (en) | 2007-07-25 | 2008-07-25 | Antibodies to cd200 and uses thereof in inhibiting immune responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013110577A Division JP5926702B2 (ja) | 2007-07-25 | 2013-05-27 | Ｃｄ２００に対する抗体および免疫応答への使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534243A JP2010534243A (ja) | 2010-11-04 |
| JP2010534243A5 true JP2010534243A5 (enExample) | 2012-07-05 |
Family
ID=40001380
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518230A Pending JP2010534243A (ja) | 2007-07-25 | 2008-07-25 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2013110577A Expired - Fee Related JP5926702B2 (ja) | 2007-07-25 | 2013-05-27 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2015135830A Pending JP2015172090A (ja) | 2007-07-25 | 2015-07-07 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2016052050A Pending JP2016117762A (ja) | 2007-07-25 | 2016-03-16 | Ｃｄ２００に対する抗体および免疫応答への使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013110577A Expired - Fee Related JP5926702B2 (ja) | 2007-07-25 | 2013-05-27 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2015135830A Pending JP2015172090A (ja) | 2007-07-25 | 2015-07-07 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2016052050A Pending JP2016117762A (ja) | 2007-07-25 | 2016-03-16 | Ｃｄ２００に対する抗体および免疫応答への使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8252285B2 (enExample) |
| EP (1) | EP2178561A1 (enExample) |
| JP (4) | JP2010534243A (enExample) |
| KR (1) | KR20100041849A (enExample) |
| AU (1) | AU2008279619B2 (enExample) |
| BR (1) | BRPI0814644A2 (enExample) |
| CA (1) | CA2697159C (enExample) |
| MX (1) | MX2010000981A (enExample) |
| WO (1) | WO2009014745A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534243A (ja) * | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Ｃｄ２００に対する抗体および免疫応答への使用 |
| MX2012009321A (es) * | 2010-02-11 | 2012-11-21 | Alexion Pharma Inc | Metodos terapeuticos que utilizan anticuerpos anti-cd200. |
| JP6150734B2 (ja) * | 2011-02-03 | 2017-06-21 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用 |
| EP3150632B1 (en) | 2011-06-10 | 2020-04-08 | Her Majesty The Queen in right of Canada, as represented by the Minister of National Defence | Anti-ricin antibodies and uses thereof |
| ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
| US9737598B2 (en) * | 2014-06-30 | 2017-08-22 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| CA2969384A1 (en) * | 2014-12-17 | 2016-06-23 | Cellectis | Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain |
| US10888609B2 (en) | 2015-11-03 | 2021-01-12 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| WO2018102594A1 (en) * | 2016-12-01 | 2018-06-07 | Alexion Pharmaceuticals, Inc. | Methods of treating solid tumors with anti-cd200 antibodies |
| KR101968246B1 (ko) * | 2017-04-27 | 2019-04-11 | 서울대학교산학협력단 | 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법 |
| WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY |
| WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
| EP3911357A1 (en) | 2019-01-14 | 2021-11-24 | Regents of the University of Minnesota | Cd200ar ligands for cancer immunotherapy |
| EP4296280A1 (en) * | 2022-06-21 | 2023-12-27 | F. Hoffmann-La Roche AG | Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
| DK1032662T3 (da) * | 1997-11-07 | 2006-07-03 | Trillium Therapeutics Inc | Fremgangsmåder og sammensætninger til immunmodulation |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| WO2004060295A2 (en) | 2002-12-27 | 2004-07-22 | Schering Corporation | Methods of inducing and maintaining immune tolerance |
| NZ599035A (en) * | 2006-01-12 | 2013-12-20 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
| CA2694121C (en) | 2007-07-25 | 2016-06-07 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune disease |
| JP2010534243A (ja) | 2007-07-25 | 2010-11-04 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Ｃｄ２００に対する抗体および免疫応答への使用 |
-
2008
- 2008-07-25 JP JP2010518230A patent/JP2010534243A/ja active Pending
- 2008-07-25 EP EP08794745A patent/EP2178561A1/en not_active Withdrawn
- 2008-07-25 BR BRPI0814644-6A2A patent/BRPI0814644A2/pt not_active IP Right Cessation
- 2008-07-25 US US12/670,379 patent/US8252285B2/en not_active Ceased
- 2008-07-25 US US14/080,457 patent/USRE46323E1/en not_active Expired - Fee Related
- 2008-07-25 AU AU2008279619A patent/AU2008279619B2/en not_active Ceased
- 2008-07-25 MX MX2010000981A patent/MX2010000981A/es active IP Right Grant
- 2008-07-25 KR KR1020107003921A patent/KR20100041849A/ko not_active Abandoned
- 2008-07-25 WO PCT/US2008/009037 patent/WO2009014745A1/en not_active Ceased
- 2008-07-25 CA CA2697159A patent/CA2697159C/en not_active Expired - Fee Related
-
2012
- 2012-06-26 US US13/533,546 patent/US8637014B2/en active Active
-
2013
- 2013-05-27 JP JP2013110577A patent/JP5926702B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-07 JP JP2015135830A patent/JP2015172090A/ja active Pending
-
2016
- 2016-03-16 JP JP2016052050A patent/JP2016117762A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534243A5 (enExample) | ||
| JP2015172090A5 (enExample) | ||
| JP2009528369A5 (enExample) | ||
| Reyes et al. | Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (Thymoglobulin®) | |
| Soliman et al. | Short‐term induction therapy with anti‐thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation | |
| RU2008139118A (ru) | Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента | |
| Krejci et al. | Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease | |
| JP5926702B2 (ja) | Ｃｄ２００に対する抗体および免疫応答への使用 | |
| JP2014505056A5 (enExample) | ||
| JP5688734B2 (ja) | 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤 | |
| Sadaka et al. | Proteasome inhibition for antibody-mediated allograft rejection | |
| Broeders et al. | Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients. | |
| Glotz et al. | Antidonor antibodies and transplantation: how to deal with them before and after transplantation | |
| Pretagostini et al. | Plasmapheresis, photopheresis, and endovenous immunoglobulin in acute antibody-mediated rejection in kidney transplantation | |
| Chuang et al. | Does immunosuppressive pharmacotherapy affect isoagglutinin titers? | |
| Boletis et al. | Delayed renal graft function: the influence of immunosuppression | |
| Anselm et al. | Prolonged basiliximab use as an alternative to calcineurin inhibition to allow renal recovery late after heart transplantation | |
| Tan et al. | Immunosuppressive preconditioning or induction regimens: evidence to date | |
| Gareau et al. | Cyclosporine immunosuppression does not prevent the production of donor-specific antibody capable of mediating allograft vasculopathy | |
| Sulemanjee et al. | The first year post–heart transplantation: Use of immunosuppressive drugs and early complications | |
| Ferrero et al. | Treatment of acute antibody-mediated rejection: a single-center experience | |
| Kahu et al. | Impact of mycophenolate mofetil intolerance on early results of kidney transplantation | |
| Schuurman | Immunosuppressives in transplant rejection | |
| Bacal et al. | Methotrexate in acute persistent humoral rejection: an option for graft rescue | |
| Krischock et al. | Induction therapy: Why, when, and which agent? |